|Articles|October 2, 2015

BioPharm International-10-15-2015
Volume 2015 eBook
Issue 2

Innovations in Automation—High-Throughput Dynamic Light Scattering for Screening Biotherapeutic Formulations

This article introduces the technology that powers automated HT–DLS and explores its practical applications in enhancing formulation stability investigations.

BioPharm International

eBooks Volume 28, Issue 14

Assessing a drug candidate’s suitability during preformulation is essential to minimize the risk of costly downstream failure. Stability is a defining feature of biotherapeutic performance; measuring formulation stability during early-phase screening allows developers to make robust predictions of suitability for further development. Read this article and other articles in

BioPharm International

's 2015

The Future of Bioprocessing

eBook.

Articles in this issue

about 11 years ago

Article

Fluctuating Capacity and Demand Conditions in Biomanufacturing

about 11 years ago

Article

Cleaning Validation for Biologics

about 11 years ago

Article

Automation of Single-Use Systems

about 11 years ago

Article

Aseptic Processing for Cytotherapy, Regenerative Medicine, and Tissue-Engineered Products

about 11 years ago

Article

Are Biopharma Patents Poised on the Post-Grant Chopping Block?

about 11 years ago

Article

Raising the Bar for Biopharma Training

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

Close-up of a hand pressing a white autoinjector pen with a red tip against a person’s upper arm. | Image Credit: © LaMorenita

November 9th, 2026

FAQ: What’s Holding Back the Shift From IV to Subcutaneous Antibodies?

More monoclonal antibodies are moving from IV infusion to subcutaneous injection, but dose, volume, and viscosity still limit the switch. This FAQ covers the formulation science, the enabling technologies, what regulators require, and what remains unresolved.

November 4th, 2026

The Promise of Microgravity for R&D and Manufacturing

As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.

FDA drug approval process, pharmaceutical regulatory compliance, food and drug administration certification, medical product approval concept, drug testing and approval | image credit: © Сергей Шиманович - © Сергей Шиманович - stock.adobe.com

November 12th, 2026

enGene Plans Year-End BLA for Detalimogene in BCG-Unresponsive NMIBC

Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.

3D illustration of Y-shaped antibodies in brown and yellow with red, many-sided payload molecules attached by purple linkers, floating near blue cells with branching extensions against a dark background. | Image Credit: © Love Employee - stock.adobe.com

November 12th, 2026

FDA Clears IND for Biolojic’s BD200, the First AI-Designed Multibody ADC to Enter Clinical Trials

FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.

Photograph of a hand gripping a blue and gray injection pen with its clear needle cover exposed, a dose dial reading “0 mg,” and a blue cap lying nearby on a white background. | Image Credit: © Yulia Antonova - stock.adobe.com

November 12th, 2026

Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development

Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.

Creative image of embryonic stem cells, cellular therapy. 3d illustration | Image Credit: © pinkeyes - © pinkeyes - stock.adobe.com

November 12th, 2026

FDA Grants Kamau RMAT Designation to Nula-cel for Sickle Cell Disease

Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.

November 11th, 2026

Q&A: Who Is Accountable When AI Gets Drug Development Wrong?

Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.

3D illustration of a translucent blue human torso, viewed from the front, with both kidneys highlighted in pink and the rib cage, liver, and intestines faintly visible. | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

November 11th, 2026

ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months

ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.

Innovations in Automation—High-Throughput Dynamic Light Scattering for Screening Biotherapeutic Formulations

Articles in this issue

Related to this article

Trending on BioPharm International

ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months

Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions

Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development

Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial

Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial